Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $125

Morgan Stanley analyst Tejas Savant maintains $Natera(NTRA.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 39.7% and a tota

Futu NewsJul 1 18:31 · Ratings

Positive Outlook for Natera Inc.: Savant Recommends Buy on Strong Study Design and Market Strategy

TipRanksJul 1 18:07

Cathie Wood's Top and Bottom Performing ARKK Holdings of H1

Seeking AlphaJun 27 22:17

Natera's New Cancer Trial to Use Signatera for Personalized Treatment

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company's personalized an

BenzingaJun 27 19:06

Express News | Natera Announces Decipher: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

BreakingsJun 27 19:00

Natera(NTRA.US) Director Sells US$296.08K in Common Stock

$Natera(NTRA.US)$ Director Sheena Jonathan sold 2,700 shares of common stock on Jun 18, 2024 at an average price of $109.6591 for a total value of $296.08K.Source: Announcement What is statement of ch

Futu NewsJun 22 09:44